![Yoshihiko Futamura](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Yoshihiko Futamura
Sociétés | Poste | Début | Fin |
---|---|---|---|
Hinge Therapeutics, Inc.
![]() Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura. | Directeur/Membre du Conseil | - | - |
Fondateur | - | - |
Historique de carrière de Yoshihiko Futamura
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Hinge Therapeutics, Inc.
![]() Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura. | Health Technology |
- Bourse
- Insiders
- Yoshihiko Futamura
- Expérience